

**Date: 13/02/2023**

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001  Script Code : 539872	National Stock Exchange of India Limited 5 <sup>th</sup> Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051  Script Code : BAJAJHCARE
--	---

Dear Sir/Madam,

**Sub** : Outcome of Board Meeting & submission of Unaudited Financial Results for the quarter and nine months ended December 31, 2022.

The Board of Directors at its Meeting held today has inter alia, considered and approved the following:

- The unaudited Financial Statements for the quarter and nine months ended December 31, 2022, as recommended by the Audit Committee; and

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, we enclose the following:

- (i) Unaudited Financial Results for the quarter ended December 31, 2022 along with limited review report;

The above information is also available on the Company's website at [www.bajajhealth.com](http://www.bajajhealth.com). This is for your information and records.

We wish to inform you that Board Meeting commenced today at 3.45 p.m. and concluded at 5.20p.m.

Kindly take the same on record.

Thanking you,

**For and on behalf of Board of Directors  
of Bajaj Healthcare Limited**

**Sajankumar Bajaj  
Chairman and Managing Director  
DIN: 00225950**

# Chaturvedi & Agrawal


## Chartered Accountants

**Independent Auditor's Review Report on the Quarterly and Nine Month Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report to  
The Board of Directors  
Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Bajaj Healthcare Limited (the "Company") for the quarter and Nine Month ended December 31, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi & Agrawal  
Chartered Accountants  
FRN: 101717W



Rasik Chaturvedi  
M. no: 039524  
UDIN: 23039524 BCYKF7831

Date: February 13, 2023  
Place: Thane



**BAJAJ HEALTHCARE LIMITED**  
( CIN No. : L99999MH1993PLC072892 )  
**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH YEAR ENDED ON December 31, 2022**  
(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended			Period Ended		Year Ended
	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>I. Revenue from operations</b>	14,188.50	20,089.37	16,757.49	51,484.75	50,417.62	67,988.98
<b>II. Other Income</b>	7.22	13.16	19.81	87.37	99.60	144.41
<b>III. Total Revenue (I+II)</b>	<b>14,195.71</b>	<b>20,102.53</b>	<b>16,777.30</b>	<b>51,572.12</b>	<b>50,517.22</b>	<b>68,133.39</b>
<b>IV. Expenses</b>						
(a) Cost of materials consumed (Including Other Direct Expenses)	10,173.94	16,501.12	8,876.40	41,890.30	35,819.06	49,982.29
(b) Changes in Inventories of Finished Good	(569.34)	(1,693.68)	3,121.48	(4,467.41)	429.20	(377.00)
(c) Employee benefits expense	1,256.18	1,358.72	1,130.99	3,606.95	3,024.41	4,110.87
(d) Finance Costs	673.59	495.14	284.47	1,551.21	813.76	1,262.38
(e) Depreciation and amortisation expense	692.32	647.76	485.88	1,993.38	1,339.69	1,763.66
(e) Other expenses	464.99	591.66	545.54	1,676.28	1,815.53	2,422.72
<b>Total Expenses</b>	<b>12,691.68</b>	<b>17,900.72</b>	<b>14,444.76</b>	<b>46,250.71</b>	<b>43,241.65</b>	<b>59,164.93</b>
<b>V. Profit Before Tax</b>	<b>1,504.03</b>	<b>2,201.81</b>	<b>2,332.54</b>	<b>5,321.41</b>	<b>7,275.57</b>	<b>8,968.46</b>
<b>VI. Tax Expense</b>						
(a) Current tax	408.00	573.00	597.00	1,407.00	1,865.00	2,250.00
(b) Earlier Years	-	-	-	-	2.04	(358.73)
(c) Deferred Tax	(9.42)	(7.07)	(8.99)	(28.79)	17.14	(61.40)
<b>Total Tax Expenses</b>	<b>398.58</b>	<b>565.93</b>	<b>588.01</b>	<b>1,378.21</b>	<b>1,884.18</b>	<b>1,829.87</b>
<b>VII. Profit (Loss) for the Period</b>	<b>1,105.45</b>	<b>1,635.87</b>	<b>1,744.53</b>	<b>3,943.20</b>	<b>5,391.39</b>	<b>7,138.59</b>
<b>VIII. Other comprehensive Income</b>						
(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	9.23
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(2.32)
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Comprehensive Income for the Period</b>	<b>1,105.45</b>	<b>1,635.87</b>	<b>1,744.53</b>	<b>3,943.20</b>	<b>5,391.39</b>	<b>7,145.49</b>
<b>IX. Paid-up Equity Share Capital (Face Value Rs. 5/-)</b>	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92
<b>X. Other Equity excluding Revaluation Reserve</b>	-	-	-	-	-	31,468.63
<b>XI. Earnings Per Share (Face Value Rs. 5/-)</b> (Not Annualised for Quarter and Half Year Ended)						
(a) Basic (in Rs.)	4.01	5.93	6.32	14.29	19.54	25.87
(b) Diluted (in Rs.)	4.01	5.93	6.32	14.29	19.54	25.87

**Note :**


a) The above Financial Results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on February 13, 2023.


b) The financial results for the Quarter and Nine Month Ended 31st December 2022 have been subjected to limited review by the statutory auditors of the Company.

c) The above audited financial results for the Quarter Ended December 31, 2022 have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 (Act) read with relevant rules-Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India.

d) The Statement as per IND AS - 108 on segment reporting is not applicable as the Management has determined that the Company dealing in Bulk Drugs and Formulation as a whole operates under single Chief Operating Decision Maker ( CODM ) w.e.f April 1st, 2022, pursuant to Organisational Restructuring.

By Order of the Board  
For Bajaj Healthcare Limited

  
Sajankumar Bajaj  
Chairman and Managing Director  
DIN : 00225950



Date: February 13, 2023  
Place: Thane